Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:19 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational Anticancer Agents to Treat Participants With Gastric and Gastroesophageal Adenocarcinoma
NCT02551055 · Millennium Pharmaceuticals, Inc. · PHASE1 · terminated · last registry update 2019-09-20 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Business Decision; No Safety Or Efficacy Concerns.” | – | Registry record, Millennium Pharmaceuticals, Inc. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PIK3CA within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2020-08-13Also stopped (withdrawn): Columbia University, Copanlisib + Romidepsin (NCT04233697)
- 2020-06-18Results posted on the registry: Novartis Pharmaceuticals, Fulvestrant + BKM120 (NCT01610284)
- 2020-05-07Results posted on the registry: Vanderbilt-Ingram Cancer Center, Enzalutamide + Taselisib (NCT02457910)
- 2020-04-28Also stopped (withdrawn): Abramson Cancer Center at Penn Medicine, Hydroxychloroquine (HCQ) + Gedatolisib (NCT03400254)
- 2020-04-08Phase 3 first posted: Adlai Nortye Biopharma Co., Ltd., Buparlisib & Paclitaxel (NCT04338399)
- 2020-03-06Results posted on the registry: NRG Oncology, Copanlisib (NCT02728258)
- 2020-03-04Results posted on the registry: Northwestern University, PI3K inhibitor BYL719 + ado-trastuzumab emtansine (NCT02038010)
- 2020-02-05Phase 3 first posted: Novartis Pharmaceuticals, alpelisib + placebo (NCT04251533)
- 2020-01-10Also stopped (terminated): Pamela Munster, Alpelisib + Cisplatin (NCT02620839)
- 2019-12-23Phase 3 first posted: Novartis Pharmaceuticals, Alpelisib + Alpelisib matching Placebo (NCT04208178)
- 2019-12-23Results posted on the registry: Bayer, Copanlisib (Aliqopa, BAY80-6946) + Metformin (NCT03655301)
- 2019-12-09Phase 3 first posted: Hoffmann-La Roche, Inavolisib + Placebo (NCT04191499)
- 2019-11-22Also stopped (withdrawn): Restorbio Inc., Dactolisib + Placebo (NCT04139915)
- 2019-11-14Results posted on the registry: Novartis Pharmaceuticals, BKM120 + Trastuzumab (NCT01816594)
- 2019-10-25Phase 3 first posted: Restorbio Inc., Dactolisib + Placebo (NCT04139915)
- 2019-10-04Also stopped (terminated): University of Florida, Gedatolisib + Paclitaxel (NCT02920450)
- 2019-10-03Results posted on the registry: University of Florida, Gedatolisib + Paclitaxel (NCT02920450)
- 2019-09-03Also stopped (terminated): Emory University, Buparlisib + Ibrutinib (NCT02614508)
- 2019-08-13Results posted on the registry: Novartis Pharmaceuticals, Fulvestrant + Alpelisib (NCT02437318)
- 2019-08-13Results posted on the registry: Canadian Cancer Trials Group, Buparlisib (NCT02340780)
- 2019-08-01Results posted on the registry: University of Oxford, BKM120 (NCT02128724)
- 2019-06-11Results posted on the registry: Sanofi, SAR245408 + SAR245409 (NCT01587040)
- 2019-05-31Phase 3 first posted: Global Coalition for Adaptive Research, Temozolomide + Lomustine (NCT03970447)
- 2019-04-10Also stopped (terminated): Cliniques universitaires Saint-Luc- Université Catholique de Louvain, BEZ235 (NCT01856101)
- 2019-03-06Results posted on the registry: SWOG Cancer Research Network, Taselisib (NCT02785913)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision